Role klinických registrů České onkologické společnosti ČLS JEP v hodnocení cílené léčby nádorových onemocnění
| Title in English | Role of the CSO clinical registries in the assessment of targeted cancer therapy |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Medicína po promoci |
| MU Faculty or unit | |
| Citation | |
| Field | Other medical specializations |
| Keywords | personalized medicine; clinical registries;Czech Society for Oncology CLS JEP |
| Description | The paper briefly summarizes main trends in progress of diagnostic and clinical registries, which represent a significant component of background information of personalized medicine, particularly in cancer care. The article further presents design and content of a set of the Czech Society for Oncology CLS JEP clinical registries that serve for the evaluation of targeted anticancer therapy in the Czech Republic. Main outcomes achieved by registries projects are documented, particularly population-based characteristics of treated patients, assessment of therapy progress, and achieved results including survival analysis. It may be concluded that comprehensive cancer centres provide this expensive therapy thoroughly and administer it to right patients, who may have the highest profit regarding their health status and cancer stage. Most of the patients undergo whole administered therapy cycle and achieve measurable therapy response. No significant number of disease progressions is recorded during the therapy and premature termination due to adverse effects is also rare. Verified results of survival analysis indicate that overall results for most of the drugs are often better than described in corresponding registration clinical studies. This fact may be explained, among others, by a strict selection of patients to undergo the targeted therapy, since the treated patients’ cohort is significantly younger in most of the medications than it would correspond to the particular disease incidence and prevalence. |